Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (AIM) is a clinical-stage biopharmaceutical company pioneering RNA-based therapeutics for cancer, viral diseases, and immune disorders. This dedicated news hub provides investors and researchers with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access verified information about Ampligen clinical progress, Alferon N Injection research, and collaborative studies with global institutions. Our curated news collection covers FDA communications, trial phase results, intellectual property updates, and scientific conference presentations.
Key updates include oncology treatment advancements, antiviral therapy research, and partnership announcements with organizations like Japan's National Institute of Infectious Diseases. Bookmark this page for real-time access to AIM's latest developments in immuno-pharmaceutical innovation.
AIM ImmunoTech (OTC Pink: AIMI), an immuno-pharma company specializing in therapeutics for cancers, immune disorders, and viral diseases including COVID-19, has announced its transition to trading under the ticker AIMI on the Pink Open Market effective April 07, 2025.
The company also confirmed its upcoming Special Meeting scheduled for April 30, 2025, where a reverse split proposal will be discussed. Shareholders can find detailed information in AIM's Definitive Proxy Statement filed on April 2, 2025.
AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused on cancer, immune disorders, and viral diseases therapeutics, announced receiving a delisting notification from NYSE American on April 4, 2025. The Exchange suspended trading of AIM's common stock due to its low selling price, citing Section 1003(f)(v) of the NYSE American Company Guide.
The company plans to appeal the determination to the Exchange's Listing Qualifications Panel, though success is not guaranteed. Trading of AIM's common stock is expected to transition to the Pink Open Market starting April 7, 2025.
AIM ImmunoTech (NYSE: AIM) has reported its Q4 and full year 2024 financial results, highlighting progress in its Ampligen clinical development programs. The company ended 2024 with $4.0 million in cash and investments, down from $13.1 million in 2023. Financial metrics show reduced expenses, with R&D costs decreasing to $6.2 million from $10.9 million and G&A expenses dropping to $13.7 million from $21.1 million year-over-year.
Key developments include the advancement of the DURIPANC Phase 1b/2 trial combining Ampligen with AstraZeneca's Imfinzi for late-stage pancreatic cancer, and upcoming milestones in multiple clinical trials through 2026. The company is also pursuing studies in refractory melanoma, triple negative breast cancer, and advanced recurrent ovarian cancer, with several trials being partially funded by collaborators including AstraZeneca and Merck.
AIM ImmunoTech (NYSE American: AIM) participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference on March 11, 2025. CEO Thomas K. Equels presented five key focus areas for 2025:
- Progress in late-stage pancreatic cancer treatment through the Phase 1b/2 DURIPANC trial at Erasmus Medical Center, Netherlands
- Expanded research in ME/CFS and post-COVID conditions
- Advancement of oncology pipeline with trials reaching major milestones
- Development of Ampligen as a vaccine adjuvant for bird flu
- Ampligen's potential as a broad-spectrum immunotherapy
The presentation is available on-demand through the company's website and investor events page.
FAQ
What is the current stock price of Aim Immunotech (AIM)?
What is the market cap of Aim Immunotech (AIM)?
